Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities

Blood

Volumn 118, Issue 3, 2011, Pages 679-685

  Perrot, Aurore ^a   Luquet, Isabelle ^b   Pigneux, Arnaud ^c   Mugneret, Francine ^d   Delaunay, Jacques ^e   Harousseau, Jean Luc ^f   Barin, Carole ^g   Cahn, Jean Yves ^h   Guardiola, Philippe ⁱ   Himberlin, Chantal ^b   Recher, Christian ^j   Vey, Norbert ^k   Lioure, Bruno ^l   Ojeda Uribe, Mario ^m   Fegueux, Nathalie ⁿ   Berthou, Christian ^o   Randriamalala, Edouard ^p   Béné, Marie C ^a   Ifrah, Norbert ⁱ   Witz, Francis ^a  

^a CHU NANCY BRABOIS   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d HÔPITAL DU BOCAGE   (France)

^e HÔTEL DIEU   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CHU BRETONNEAU   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j CHU PURPAN   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l HÔPITAL DE HAUTEPIERRE   (France)

^m Mulhouse General Hospital   (France)

ⁿ LAPEYRONIE HOSPITAL   (France)

^o BREST UNIVERSITY HOSPITAL   (France)

^p POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; LOMUSTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 3Q; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; ELDERLY CARE; FEMALE; GENETIC ASSOCIATION; HAZARD RATIO; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 79960661181     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307264     Document Type: Article

References (27)

1. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne del l'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332(4):217-223.
2. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia: the Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90(8):2978-2986. (Pubitemid 27444191)
3. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a meta-analysis. Cancer. 2005;103(8):1652-1658. (Pubitemid 40490026)
4. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187.
5. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
6. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia: the BGMT group. Leukemia. 1995;9(9):1491-1498.
7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
9. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
10. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485. (Pubitemid 38140076)
11. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63-73. (Pubitemid 43996625)
12. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280-3288.
13. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
14. Medeiros B, Othus M, Fang M, Roulston D, Appelbaum F. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224-2228.
15. Wahlin A, Markevärn B, Golovleva I, Nillson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001;115(1):25-33. (Pubitemid 32995089)
16. Witz F, Harousseau J, Sadoun A, et al. A randomized study of fludarabine in part of induction and post-remission treatment for de novo acute myeloid leukemia (AML) in elderly patients [abstract]. Blood. 2000;96(11):2168.
17. Pigneux A, Himberlin C, Hunault-Berger M, et al. Improved outcome with androgens as maintenance treatment in elderly patients with acute myeloid leukemia after ICL regimen as induction therapy: results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial [abstract]. Blood. 2008;112(11):556.
18. Harousseau J, Recher C, Vey N, et al. Gemtuzumab-ozogamicin (GO) plus idarubicin (I) and cytarabine (C) as induction treatment for elderly patients with poor-risk cytogenetics acute myeloid leukemia (AML) [abstract]. Blood. 2007;110(11):1839.
19. Mitelman F. ISCN, An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
21. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 patients younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
22. Gröschel S, Lugthart S, Schlenk R, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-2107.
23. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in AML patients. Biol Blood Marrow Transplant. 2011;17(3):356-364.
24. Downie B, Erba H, Stone R, Rizzieri D, Foran J. Monosomal karyotype is predictive of poor response to therapy and worse overall survival in secondary acute myeloid leukemia (sAML): analysis of a multi-center phase II study of amonafide and cytarabine induction therapy [abstract]. Blood. 2009;114(22):2076.
25. Granada I, Brunet S, Hoyos M, et al. Prognostic value of monosomal karyotype in patients with primary acute myeloid leukemia on behalf of Spanish CETLAM Group [abstract]. Blood. 2009;114(22):1003.
26. Seetharam M, Weinberg O, Ren L, et al. AML patients with monosomal karyotype are characterized by absence of NPM1 and FLT3 mutations and worse clinical outcome [abstract]. Blood. 2009;114(22):2638.
27. Van Gelder M, Schetelig J, Volin L, et al. Monosomal karyotype predicts poor outcome for MDS/sAML patients with chromosome 7 abnormalities after allogeneic stem cell transplantation for MDS/sAML: a study of the MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 2009;114(22):293.